TransPharma Medical Receives Second Milestone Payment from Teva Pharmaceutical Industries
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced it has received its second milestone payment from Teva Pharmaceutical Industries for the successful development of a stable human growth hormone (hGH) dry form patch required for advanced clinical trials of Teva's transdermal hGH product.
The milestone achieved is in line with the product development plan of hGH, the first of up to five molecules designated for joint development by TransPharma and Teva in an agreement originally signed between the two companies in 2004. Under the agreement, Teva will exclusively market each of the drug products and will pay TransPharma milestone payments, royalties, and development costs.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Defect in fruit fly respiratory system may provide insights into human aortic aneurysms

Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection
Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition
Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology
